CL2023002914A1 - Dosificación y administración de l-asparaginasa recombinante - Google Patents
Dosificación y administración de l-asparaginasa recombinanteInfo
- Publication number
- CL2023002914A1 CL2023002914A1 CL2023002914A CL2023002914A CL2023002914A1 CL 2023002914 A1 CL2023002914 A1 CL 2023002914A1 CL 2023002914 A CL2023002914 A CL 2023002914A CL 2023002914 A CL2023002914 A CL 2023002914A CL 2023002914 A1 CL2023002914 A1 CL 2023002914A1
- Authority
- CL
- Chile
- Prior art keywords
- asparaginase
- dosing
- recombinant
- administration
- human subject
- Prior art date
Links
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 title abstract 2
- 108010024976 Asparaginase Proteins 0.000 title abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención proporciona composiciones y métodos para tratar una enfermedad tratable mediante la disminución de asparagina en un sujeto humano que comprende administrar a un sujeto humano L-asparaginasa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163168224P | 2021-03-30 | 2021-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023002914A1 true CL2023002914A1 (es) | 2024-04-05 |
Family
ID=76375640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023002914A CL2023002914A1 (es) | 2021-03-30 | 2023-09-29 | Dosificación y administración de l-asparaginasa recombinante |
Country Status (11)
Country | Link |
---|---|
US (2) | US20220313798A1 (es) |
EP (1) | EP4313121A1 (es) |
JP (1) | JP2024512784A (es) |
KR (1) | KR20230163490A (es) |
CN (1) | CN117355325A (es) |
AU (1) | AU2022246850A1 (es) |
CA (1) | CA3213527A1 (es) |
CL (1) | CL2023002914A1 (es) |
CO (1) | CO2023014650A2 (es) |
MX (1) | MX2023011508A (es) |
WO (2) | WO2022211829A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220313798A1 (en) * | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
US4755465A (en) | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
US5281532A (en) | 1983-07-27 | 1994-01-25 | Mycogen Corporation | Pseudomas hosts transformed with bacillus endotoxin genes |
US4695462A (en) | 1985-06-28 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of biological pesticides |
US4695455A (en) | 1985-01-22 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of pesticides produced by expression of heterologous genes |
GB8517071D0 (en) | 1985-07-05 | 1985-08-14 | Hoffmann La Roche | Gram-positive expression control sequence |
US5128130A (en) | 1988-01-22 | 1992-07-07 | Mycogen Corporation | Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens |
US5055294A (en) | 1988-03-03 | 1991-10-08 | Mycogen Corporation | Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens |
US5169760A (en) | 1989-07-27 | 1992-12-08 | Mycogen Corporation | Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters |
GB9017002D0 (en) | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
US20050186666A1 (en) | 2003-11-19 | 2005-08-25 | Dow Global Technologies Inc. | Protein expression systems |
PL2336153T3 (pl) | 2003-11-21 | 2016-08-31 | Pfenex Inc | Udoskonalone systemy ekspresji z układem wydzielania SEC |
EP2412816B1 (en) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Process for improved protein expression by strain engineering |
FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
WO2007103290A2 (en) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
WO2007142954A2 (en) | 2006-05-30 | 2007-12-13 | Dow Global Technologies Inc. | Codon optimization method |
CA2677179C (en) | 2007-01-31 | 2016-02-16 | Dow Global Technologies Inc. | Bacterial leader sequences for increased expression |
JP2010524448A (ja) | 2007-04-20 | 2010-07-22 | ディーエスエム アイピー アセッツ ビー.ブイ. | 新規のアスパラギナーゼおよびその使用 |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
EP2142651B1 (en) | 2007-04-27 | 2013-05-22 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
JP5839411B2 (ja) | 2010-03-30 | 2016-01-06 | フェニックス インク. | 組み換え型毒素タンパク質の高レベルの発現 |
CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
SG11201912625QA (en) | 2017-06-21 | 2020-01-30 | Jazz Pharmaceuticals Ireland Ltd | Modified l-asparaginase |
EP3418383A1 (en) * | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
EP3700921A4 (en) | 2017-10-27 | 2021-12-15 | Pfenex Inc. | PROCESS FOR THE PRODUCTION OF RECOMBINANT ERWINIA ASPARAGINASE |
JP2021505661A (ja) | 2017-11-30 | 2021-02-18 | ジャズ ファーマシューティカルズ アイルランド リミテッド | アスパラギナーゼを用いた治療法 |
US20210299233A1 (en) * | 2018-07-12 | 2021-09-30 | The Children's Medical Center Corporation | Method for treating cancer |
GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
TW202134258A (zh) * | 2019-10-25 | 2021-09-16 | 愛爾蘭商爵士製藥愛爾蘭公司 | 重組l—天冬醯胺酸酶 |
US20220313798A1 (en) * | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
-
2021
- 2021-05-14 US US17/321,318 patent/US20220313798A1/en active Pending
- 2021-05-14 WO PCT/US2021/032627 patent/WO2022211829A1/en active Application Filing
-
2022
- 2022-03-30 EP EP22719079.0A patent/EP4313121A1/en active Pending
- 2022-03-30 WO PCT/US2022/022635 patent/WO2022212571A1/en active Application Filing
- 2022-03-30 JP JP2023560959A patent/JP2024512784A/ja active Pending
- 2022-03-30 MX MX2023011508A patent/MX2023011508A/es unknown
- 2022-03-30 KR KR1020237037001A patent/KR20230163490A/ko unknown
- 2022-03-30 AU AU2022246850A patent/AU2022246850A1/en active Pending
- 2022-03-30 US US17/709,166 patent/US20220323556A1/en active Pending
- 2022-03-30 CA CA3213527A patent/CA3213527A1/en active Pending
- 2022-03-30 CN CN202280029275.0A patent/CN117355325A/zh active Pending
-
2023
- 2023-09-29 CL CL2023002914A patent/CL2023002914A1/es unknown
- 2023-10-27 CO CONC2023/0014650A patent/CO2023014650A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2023011508A (es) | 2023-12-07 |
JP2024512784A (ja) | 2024-03-19 |
CN117355325A (zh) | 2024-01-05 |
CA3213527A1 (en) | 2022-10-06 |
AU2022246850A1 (en) | 2023-10-12 |
WO2022211829A1 (en) | 2022-10-06 |
KR20230163490A (ko) | 2023-11-30 |
AU2022246850A9 (en) | 2023-10-26 |
WO2022212571A1 (en) | 2022-10-06 |
US20220313798A1 (en) | 2022-10-06 |
CO2023014650A2 (es) | 2023-11-20 |
EP4313121A1 (en) | 2024-02-07 |
US20220323556A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022007677A2 (pt) | L-asparaginase recombinante | |
CO2019006292A2 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares | |
CO2018005361A2 (es) | Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración | |
BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
CR11724A (es) | Agente para tratar enfermedades | |
BR112014015955A8 (pt) | uso terapêutico subcutâneo de inibidor de dpp-4 | |
PH12020551427A1 (en) | Epinephrine spray formulations | |
BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
CO6311006A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas | |
CR11723A (es) | Agente para tratar enfermedad | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
CL2023002914A1 (es) | Dosificación y administración de l-asparaginasa recombinante | |
CO6220969A2 (es) | Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo | |
PH12020550821A1 (en) | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration | |
AR112166A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b | |
CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
UY34896A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
CL2020000508A1 (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos. | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
BR112015012497A2 (pt) | combinações farmacêuticas |